C.M.F. Kruijtzer

Increased Oral Bioavailability of Topotecan in Combination With the Breast Cancer Resistance Protein and P-Glycoprotein Inhibitor GF120918

C.M.F. Kruijtzer, Jos H. Beijnen, Hilde Rosing et al. · Journal of Clinical Oncology · 2002 · 462 citations

Pharmacy, Pharmacokinetics, Pharmacology +13

Phase II and Pharmacologic Study of Weekly Oral Paclitaxel Plus Cyclosporine in Patients With Advanced Non–Small-Cell Lung Cancer

C.M.F. Kruijtzer, Jan H.M. Schellens, J. Mezger et al. · Journal of Clinical Oncology · 2002 · 58 citations

Medicine, Oncology, Pharmacology +14

Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer

C.M.F. Kruijtzer, Henk Boot, Jos H. Beijnen et al. · Annals of Oncology · 2003 · 46 citations

Medicine, Oncology, Pharmacology +7

Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer

Helgi H. Helgason, C.M.F. Kruijtzer, Alwin D. R. Huitema et al. · British Journal of Cancer · 2006 · 39 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17